KALA:NAS (USA) Also trade in: Germany

Kala Pharmaceuticals Inc

$ 7.52 -0.08 (-1.05%)
Volume: 84,228 Avg Vol (1m): 232,743
Market Cap $: 254.80 Mil Enterprise Value $: 182.88 Mil
P/E (TTM): 0.00 P/B: 2.39
Earnings Power Value 0
Net Current Asset Value 1.83
Tangible Book 2.26
Projected FCF 0
Median P/S Value 0
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 5/10

Current vs industry vs history
Cash-to-Debt 1.73
Debt-to-Equity 0.94
Debt-to-EBITDA -1.58
Piotroski F-Score 3
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -0.02
DISTRESS
GREY
SAFE

Profitability & Growth : 2/10

Current vs industry vs history
ROE % -83.85
ROA % -53.63
ROC (Joel Greenblatt) % -4810.83
3-Year Total Revenue Growth Rate -100.00
N/A
3-Year Total EBITDA Growth Rate -58.30
N/A

» KALA's 30-Y Financials

Financials (Next Earnings Date: 2019-05-10)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:KALA

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare SZSE:300653 NAS:PRTK SHSE:603538 NAS:GTXI NAS:INSY OTCPK:RCAR NAS:PTGX NAS:INO NAS:CORI XKRX:182400 LSE:CIR TSXV:EMH NAS:MRSN NAS:STML TSX:AUP SHSE:603229 NAS:SYRS NAS:NITE XMCE:PHM NAS:ADVM
Traded in other countries 27F.Germany
Address 100 Beaver Street, Suite 201, Waltham, MA, USA, 02453
Kala Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development and commercialization of therapeutics using its proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases. The company's MPPs are selectively-sized nanoparticles and have proprietary coatings. It has applied the MPP technology to create nanosuspensions of loteprednol etabonate, or LE, a corticosteroid designed for ocular applications, resulting in two product candidates in Phase 3 clinical development, KPI-121 1.0% for the treatment of inflammation and pain following ocular surgery and KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease.

Ratios

Current vs industry vs history
PB Ratio 2.39
EV-to-EBIT -2.88
EV-to-EBITDA -2.92
Current Ratio 10.41
Quick Ratio 10.17

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -15.70
N/A

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 3.33
Earnings Yield (Joel Greenblatt) % -34.64

More Statistics

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 3
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N